Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy

Bibliography

• Napoli C, Lemieux C, Jorgensen R. Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans. Plant Cell 1990;2(4):279-89
   PubMed Web of Science ®Google Scholar
• Ketzinel-Gilad M, Shaul Y, Galun E. RNA interference for antiviral therapy. J Gene Med 2006;8(8):933-50
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391(6669):806-811
   PubMed Web of Science ®Google Scholar
• Zamore PD, Tuschl T, Sharp PA, et al. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000;101(1):25-33
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-8
   PubMed Web of Science ®Google Scholar
• Kim K, Lee YS, Harris D, et al. The RNAi pathway initiated by Dicer-2 in Drosophila. Cold Spring Harb Symp Quant Biol 2006;71:39-44
   PubMedGoogle Scholar
• Li CX, Parker A, Menocal E, et al. Delivery of RNA interference. Cell Cycle 2006;5(18):2103-9
   PubMed Web of Science ®Google Scholar
• Dave RS, Pomerantz RJ. RNA interference: on the road to an alternate therapeutic strategy! Rev Med Virol 2003;13(6):373-85
   PubMed Web of Science ®Google Scholar
• Hoerter JA, Walter NG. Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. RNA 2007;13(11):1887-93
   PubMed Web of Science ®Google Scholar
• Butowski N, Chang SM. Small molecule and monoclonal antibody therapies in neurooncology. Cancer Control 2005;12(2):116-24
   PubMedGoogle Scholar
• Qi JH, Claesson-Welsh L. VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp Cell Res 2001;263(1):173-82
   PubMed Web of Science ®Google Scholar
• Hadj-Slimane R, Lepelletier Y, Lopez N, et al. Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis. Biochimie 2007;89(10):1234-44
   PubMed Web of Science ®Google Scholar
• Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today 2006;11(1-2):67-73
   PubMed Web of Science ®Google Scholar
• Das B, Yeger H, Tsuchida R, et al. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res 2005;65(16):7267-75
   PubMed Web of Science ®Google Scholar
• List AF, Glinsmann-Gibson B, Stadheim C, et al. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol 2004;32(6):526-35
   PubMed Web of Science ®Google Scholar
• Kou R, SenBanerjee S, Jain MK, et al. Differential regulation of vascular endothelial growth factor receptors (VEGFR) revealed by RNA interference: interactions of VEGFR-1 and VEGFR-2 in endothelial cell signaling. Biochemistry 2005;44(45):15064-73
   PubMed Web of Science ®Google Scholar
• Huang C, Li M, Chen C, et al. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 2008;12(5):637-45
   PubMed Web of Science ®Google Scholar
• Wieczorek M, Paczkowska A, Guzenda P, et al. Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells. Cancer Biol Ther 2008;7(2):268-74
   PubMed Web of Science ®Google Scholar
• Rosell R, Cecere F, Cognetti F, et al. Future directions in the second-line treatment of non-small cell lung cancer. Semin Oncol 2006;33(1 Suppl 1):S45-51
   PubMed Web of Science ®Google Scholar
• Guo J, Verma UN, Gaynor RB, et al. Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res 2004;10(10):3333-41
   PubMed Web of Science ®Google Scholar
• Guo J, Fu YC, Becerra CR. Dissecting role of regulatory factors in NF-kappaB pathway with siRNA. Acta Pharmacol Sin 2005;26(7):780-8
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Yagi H, Yotsumoto F, et al. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule. Anticancer Res 2007;27(6A):3713-21
   PubMed Web of Science ®Google Scholar
• Jones HE, Gee JM, Hutcheson IR, et al. Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer 2006;13(Suppl 1):S45-51
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl 4):S9-15
   PubMedGoogle Scholar
• Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12(18):5268-72
   PubMed Web of Science ®Google Scholar
• Li SD, Chen YC, Hackett MJ, et al. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 2008;16(1):163-9
   PubMed Web of Science ®Google Scholar
• Diehl KM, Grewal N, Ethier SP, et al. p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal. J Surg Res 2007;142(1):162-9
   PubMed Web of Science ®Google Scholar
• Zhou BP, Liao Y, Xia W, et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3(11):973-82
   PubMed Web of Science ®Google Scholar
• Yoshizawa T, Hattori Y, Hakoshima M, et al. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur J Pharm Biopharm 2008
   PubMedGoogle Scholar
• Wang R, Lin F, Wang X, et al. The therapeutic potential of survivin promoter-driven siRNA on suppressing tumor growth and enhancing radiosensitivity of human cervical carcinoma cells via downregulating hTERT gene expression. Cancer Biol Ther 2007;6(8):1295-301
   PubMed Web of Science ®Google Scholar
• Shen Y, Zhang YW, Zhang ZX, et al. hTERT-targeted RNA interference inhibits tumorigenicity and motility of HCT116 cells. Cancer Biol Ther 2008;7(2):228-36
   PubMed Web of Science ®Google Scholar
• Wang H, Nan L, Yu D, et al. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res 2001;7(11):3613-24
   PubMed Web of Science ®Google Scholar
• Martinez LA, Naguibneva I, Lehrmann H, et al. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 2002;99(23):14849-54
   PubMed Web of Science ®Google Scholar
• Lawen A. Apoptosis – an introduction. Bioessays 2003;25(9):888-96
   PubMed Web of Science ®Google Scholar
• Hao JH, Gu QL, Liu BY, et al. Inhibition of the proliferation of human gastric cancer cells SGC-7901 in vitro and in vivo using Bcl-2 siRNA. Chin Med J (Engl) 2007;120(23):2105-111
   PubMed Web of Science ®Google Scholar
• Nieth C, Priebsch A, Stege A, et al. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 2003;545(2-3):144-50
   PubMed Web of Science ®Google Scholar
• Chen SM, Wang Y, Xiao BK, et al. Effect of blocking VEGF, hTERT and Bcl-xl by multiple shRNA expression vectors on the human laryngeal squamous carcinoma xenograft in nude mice. Cancer Biol Ther 2007;7(5)
   Google Scholar
• Li SD, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 2008;16(5):942-6
   PubMed Web of Science ®Google Scholar
• Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA 2004;101(7):1892-7
   PubMed Web of Science ®Google Scholar
• Pirollo KF, Chang EH. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res 2008;68(5):1247-50
   PubMed Web of Science ®Google Scholar
• Grimm D, Pandey K, Kay MA. Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol 2005;392:381-405
   PubMed Web of Science ®Google Scholar
• Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004;15(12):1157-66
   PubMed Web of Science ®Google Scholar
• Meyer M, Wagner E. Recent developments in the application of plasmid DNA-based vectors and small interfering RNA therapeutics for cancer. Hum Gene Ther 2006;17(11):1062-76
   PubMed Web of Science ®Google Scholar
• De Paula D, Bentley MV, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 2007;13(4):431-56
   PubMed Web of Science ®Google Scholar
• Sato A, Choi SW, Hirai M, et al. Polymer brush-stabilized polyplex for a siRNA carrier with long circulatory half-life. J Control Release 2007;122(3):209-16
   PubMed Web of Science ®Google Scholar
• Bartlett DW, Davis ME. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 2007;18(2):456-68
   PubMed Web of Science ®Google Scholar
• Kakizawa Y, Furukawa S, Ishii A, et al. Organic–inorganic hybrid-nanocarrier of siRNA constructing through the self-assembly of calcium phosphate and PEG-based block aniomer. J Control Release 2006;111(3):368-70
   PubMed Web of Science ®Google Scholar
• Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995;92(16):7297-301
   PubMed Web of Science ®Google Scholar
• Vasir JK, Labhasetwar V. Polymeric nanoparticles for gene delivery. Expert Opin Drug Deliv 2006;3(3):325-44
   PubMed Web of Science ®Google Scholar
• Bolcato-Bellemin AL, Bonnet ME, Creusat G, et al. Sticky overhangs enhance siRNA-mediated gene silencing. Proc Natl Acad Sci USA 2007;104(41):16050-5
   PubMed Web of Science ®Google Scholar
• Werth S, Urban-Klein B, Dai L, et al. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. J Control Rel 2006;112(2):257-70
   PubMed Web of Science ®Google Scholar
• Andersen MO, Howard KA, Paludan SR, et al. Delivery of siRNA from lyophilized polymeric surfaces. Biomaterials 2008;29(4):506-12
   PubMed Web of Science ®Google Scholar
• Rozema DB, Lewis DL, Wakefield DH, et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 2007;104(32):12982-7
   PubMed Web of Science ®Google Scholar
• Novobrantseva TI, Akinc A, Borodovsky A, et al. Delivering silence: advancements in developing siRNA therapeutics. Curr Opin Drug Discov Devel 2008;11(2):217-24
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441(7089):111-4
   PubMed Web of Science ®Google Scholar
• Halder J, Kamat AA, Landen CN Jr, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12(16):4916-24
   PubMed Web of Science ®Google Scholar
• Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008;100(5):359-72
   PubMed Web of Science ®Google Scholar
• Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23(8):1002-7
   PubMed Web of Science ®Google Scholar
• Ueno NT, Bartholomeusz C, Xia W, et al. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res 2002;62(22):6712-6
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Surface-modified LPD nanoparticles for tumor targeting. Ann NY Acad Sci 2006;1082:1-8
   PubMed Web of Science ®Google Scholar
• Auguste DT, Furman K, Wong A, et al. Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes. J Control Release 2008;
   PubMedGoogle Scholar
• Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32(19):e149
   PubMed Web of Science ®Google Scholar
• de Wolf HK, Snel CJ, Verbaan FJ, et al. Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. Int J Pharm 2007;331(2):167-175
   PubMed Web of Science ®Google Scholar
• Leng Q, Scaria P, Zhu J, et al. Highly branched HK peptides are effective carriers of siRNA. J Gene Med 2005;7(7):977-86
   PubMed Web of Science ®Google Scholar
• Christian S, Pilch J, Akerman ME, et al. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003;163(4):871-78
   PubMed Web of Science ®Google Scholar
• Porkka K, Laakkonen P, Hoffman JA, et al. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo Proc Natl Acad Sci USA 2002;99(11):7444-9
   PubMed Web of Science ®Google Scholar
• Derfus AM, Chen AA, Min DH, et al. Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem 2007;18(5):1391-6
   PubMed Web of Science ®Google Scholar
• Shao K, Hou Q, Go ML, et al. Sulfatide-tenascin interaction mediates binding to the extracellular matrix and endocytic uptake of liposomes in glioma cells. Cell Mol Life Sci 2007;64(4):506-15
   PubMed Web of Science ®Google Scholar
• Xia CF, Zhang Y, Boado RJ, et al. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 2007;24(12):2309-16
   PubMed Web of Science ®Google Scholar
• Pirollo KF, Rait A, Zhou Q, et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007;67(7):2938-43
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Heidel JD, Bartlett DW, et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65(19):8984-92
   PubMed Web of Science ®Google Scholar
• Tietze N, Pelisek J, Philipp A, et al. Induction of Apoptosis in Murine Neuroblastoma by Systemic Delivery of Transferrin-Shielded siRNA Polyplexes for Downregulation of Ran. Oligonucleotides 2008;18(2):161-74
   PubMed Web of Science ®Google Scholar
• Bartlett DW, Su H, Hildebrandt IJ, et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007;104(39):15549-54
   PubMed Web of Science ®Google Scholar
• Cerchia L, Hamm J, Libri D, et al. Nucleic acid aptamers in cancer medicine. FEBS Lett 2002;528(1-3):12-6
   PubMed Web of Science ®Google Scholar
• McNamara JO 2nd, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24(8):1005-15
   PubMed Web of Science ®Google Scholar
• Chono S, Li S-D, Huang L. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. Journal of Controlled Release 2008;
   Google Scholar
• Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14(5):1310-6
   PubMed Web of Science ®Google Scholar
• Colin M, Maurice M, Trugnan G, et al. Cell delivery, intracellular trafficking and expression of an integrin-mediated gene transfer vector in tracheal epithelial cells. Gene Ther 2000;7(2):139-52
   PubMed Web of Science ®Google Scholar